ENVIRONMENTAL ENRICHMENT EFFECTS IN AD TRANSGENIC MICE
AD 转基因小鼠的环境富集效应
基本信息
- 批准号:6932636
- 负责人:
- 金额:$ 8.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-04-01 至 2010-03-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Although retrospective studies suggest that a lifelong pattern of high mental activity is protective against Alzheimer's Disease (AD), prospective longitudinal studies have not been done. As well, the contribution of social and/or physical activity to AD risk-reduction has not been adequately evaluated in controlled clinical studies nor has the potential benefit of long-term, intensive cognitive rehabilitation in AD patients. The availability of AD transgenic mice make it possible to investigate these issues in fully-controlled longitudinal studies. Our preliminary studies indicate that "complete" environmental enrichment (e.g., cognitive, social, and physical activity) is both protective and therapeutic against cognitive impairment in AD transgenic mice ? this, without affecting brain beta-amyloid deposition. The present project will first elucidate the role of each
contributing component (e.g., cognitive,social, and physical) to the protective ability of complete
environmental enrichment; this isolation of enrichment's contributing components is impossible to achieve in clinical studies. Second, this project will evaluate the potential of both continous and session-restricted environmental enrichment as a treatment to cognitively-impaired AD transgenic mice. All cognitive rehabilitative therapeutic in AD patients are session-restricted, so it is important to investigate this protocol in AD transgenic models. Third, a variety of brain neuropathologic and neurochemical processes will be assessed that could be mechanistically involved in the cognitive benefits provided by environmental enrichment or it's various component activities. These processes include neurogenesis, neurodegeneration, oxidative stress, neuroinflammation, and growth factor modulation. Collectively, the studies of this project
are of substantial public health significance because they investigate the potential for "modifiable" factors (cognitive, social, physical activity) to protective against or treat AD, as well as provide important insight into likely cellular/molecular mechanisms that may be involved therein.
尽管回顾性研究表明,终生高精神活动模式对阿尔茨海默病(AD)有保护作用,但前瞻性纵向研究尚未完成。此外,社会和/或身体活动对AD风险降低的贡献尚未在对照临床研究中得到充分评估,也没有AD患者长期强化认知康复的潜在益处。AD转基因小鼠的可用性使得在完全控制的纵向研究中调查这些问题成为可能。我们的初步研究表明,“完全”的环境富集(如认知、社会和身体活动)对AD转基因小鼠的认知损伤既有保护作用,也有治疗作用。这在不影响大脑β -淀粉样蛋白沉积的情况下进行。本项目将首先阐明每一个的作用
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GARY W ARENDASH其他文献
GARY W ARENDASH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GARY W ARENDASH', 18)}}的其他基金
BRAIN TISSUE TRANSPLANTS AND REPRODUCTIVE PROCESSES
脑组织移植和生殖过程
- 批准号:
3447955 - 财政年份:1983
- 资助金额:
$ 8.41万 - 项目类别:
ENVIRONMENTAL ENRICHMENT EFFECTS IN AD TRANSGENIC MICE
AD 转基因小鼠的环境富集效应
- 批准号:
7309938 - 财政年份:
- 资助金额:
$ 8.41万 - 项目类别:
ENVIRONMENTAL ENRICHMENT EFFECTS IN ALZHEIMER'S DISEASE TRANSGENIC MICE
环境富集对阿尔茨海默病转基因小鼠的影响
- 批准号:
7797416 - 财政年份:
- 资助金额:
$ 8.41万 - 项目类别:
ENVIRONMENTAL ENRICHMENT EFFECTS IN ALZHEIMER'S DISEASE TRANSGENIC MICE
环境富集对阿尔茨海默病转基因小鼠的影响
- 批准号:
7591633 - 财政年份:
- 资助金额:
$ 8.41万 - 项目类别:
ENVIRONMENTAL ENRICHMENT EFFECTS IN ALZHEIMER'S DISEASE TRANSGENIC MICE
环境富集对阿尔茨海默病转基因小鼠的影响
- 批准号:
7425024 - 财政年份:
- 资助金额:
$ 8.41万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 8.41万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 8.41万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 8.41万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 8.41万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 8.41万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 8.41万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 8.41万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 8.41万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 8.41万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 8.41万 - 项目类别: